Molecular Response Announces Key Agreement in Translational Oncology with OncoMed Pharmaceuticals
Complete the form below to unlock access to ALL audio articles.
OncoMed is a privately held clinical development stage biopharmaceutical company developing therapeutics that target the biologic pathways critical to tumor initiating cells, also known as "cancer stem cells." Under the terms of the agreement, the collaboration will deliver molecularly characterized PDX models for multiple cancer indications, with full utilization of Molecular Response's highly optimized pre-screening and characterization methodologies. This will allow OncoMed to expand their already extensive bank of proprietary xenograft models derived from freshly resected human cancers based on the molecular profile of the tumors as well as complement OncoMed's existing biomarker and patient selection efforts. Financial terms of the collaboration were not disclosed.
"The expansion of our tumor bank in this selective manner will enhance our efforts of developing predictive biomarkers alongside the development of our anti-cancer stem cell therapeutics," said Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals.
"Development of characterized PDX models is a natural addition to our core competencies in working with patient-derived primary tumor cells. OncoMed is a leader in cancer stem cell therapeutics and a most discerning partner in evaluation of new PDX models. The expanded collaboration with OncoMed is proof of our success and continued commitment to enable further evaluation of cancer therapeutics in better characterized models with use of our high content cell-based platforms and exclusive patient-derived primary tumor cell bank," said Cyrus K. Mirsaidi, Molecular Response CEO.